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Summary
What is already known on this topic?
Patients who take addictive pain relievers often have chronic conditions.
What is added by this report?
From 2011 to 2015, more than 90% of US opioid-related hospitalizations
were among patients with 2 or more chronic diseases. The trend in opioid-
related hospitalization among patients with multiple chronic diseases is in-
creasing and noteworthy.
What are the implications for public health practice?
Multiple chronic diseases are associated with opioid-related hospitaliza-
tions, indicating that prevention of opioid-related abuse and overdose
among patients with multiple chronic conditions requires alternatives to
opioid prescription, when possible.
Abstract
Chronic disease and opioid-related hospitalizations in the United
States are increasing. We analyzed nationally representative data
on patients aged 18 years or older from the 2011–2015 National
Inpatient Sample to assess the association between opioid-related
hospitalization and chronic diseases. We found that most patients
with opioid-related hospitalization were white, aged 35–54 years,
in urban hospitals, and had 2 or more comorbid conditions. Pa-
tients with 2 or more chronic conditions accounted for more than
90% of opioid-related hospitalizations in all years. The results
suggest a need for targeted interventions to prevent opioid misuse
in patients with multiple chronic conditions.
Objective
Patients with chronic conditions such as cancer, stroke, asthma,
and obesity often experience chronic pain and have a higher likeli-
hood of receiving one or more opioid prescriptions (1). In this
study, we examined whether the prevalence of opioid-related hos-
pitalization was associated with chronic diseases among inpatients.
This study is the first to examine the prevalence of opioid-related
hospitalization and chronic disease among patients admitted to
community hospitals. Opioid-related inpatient stays (2) have in-
creased, mainly due to opioid abuse, addiction, poisoning, and de-
pendence, resulting from misuse of opioid pain relievers that are
often originally prescribed (3) to treat chronic pain.
Methods
In this cross-sectional study, we analyzed data on patients aged 18
years or  older from the National  Inpatient  Sample (NIS) from
January 1, 2011, to September 30, 2015. Claims occurring from
October through December of 2015 were not included because of
the transition from the International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM) to the 10th revision
(ICD-10-CM) coding system on October 1, 2015. We included
arthritis, spinal disease, asthma, liver disease, stroke, cancer, and
obesity because these diseases are most likely to be prescribed
opioids in the internal and family medicine specialties. Family
medicine (21.8%) and internal medicine (17.6%) reportedly write
the most opioid prescriptions, followed by physical medicine/re-
habilitation, anesthesiology/pain, hematology/oncology, and neur-
ology (4–6). Relationships between asthma and opioid abuse and
dependence (7) and between chronic liver disease and opioid use
(8) have been established, as has a relationship between stroke and
opioid abuse among young stroke patients (9). Cancer patients rely
on opioid medications for relief from cancer pain (10). Obesity
was included because of its significant association with chronic
pain (11). Using the NIS sample, we identified 3,239,136 opioid-
related hospitalization cases for from January 1, 2011, to Septem-
ber 30, 2015.
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We combined opioid dependence and unspecified use, adverse ef-
fects of opioids, opioid abuse, and opioid poisoning to create a
single variable, opioid-related hospitalization (specific ICD-9-CM
codes  are  available  in  Appendices  A  and  B).  The  data  were
weighted by using sampling weights provided by the NIS Health-
care Cost and Utilization Project (12). For creating national estim-
ates for the prevalence of opioid-related hospitalizations and all
analyses, we implemented Stata’s trend weight (TRENDWT) for
2011 and discharge weight (DISCWT) from 2012 through 2015
(StataCorp LLC). Because of the redesign of NIS data in 2012, we
used TRENDWT for 2011, which allowed the national estimates
for  trend  analysis  in  2011  to  be  consistent  with  data  from
2012–2015. To use trend weight, we merged the trend weight file
(www.hcup-us.ahrq.gov/db/nation/nis/trendwghts.jsp) into the ori-
ginal NIS 2011 data. We analyzed the trends in opioid-related hos-
pitalizations by type of chronic disease for 2011–2015 and used
the Pearson χ2 test to test for significance. Significance was set at
P < .05.
Results
The highest total number of opioid-related hospitalization cases
was in 2014 (n = 704,670) (Table 1).  From 2011 to 2015,  the
highest prevalence of opioid-related hospitalization was among
patients aged 35–54 years (5-year average, 37%), followed by
those aged 18–34 years. The percentages of men and women with
opioid-related hospitalizations were approximately equal.  The
highest prevalence of opioid-related hospitalization was among
white patients (5-year average, 72%), and the second-highest was
among black patients (5-year average, 15%). The prevalence was
higher in urban hospitals (5-year prevalence range, 58%–64%)
than in rural hospitals (5-year prevalence range, 36%–42%). The
prevalence was also higher among patients who used Medicaid
and Medicare than among those who did not. The prevalence of
opioid-related hospitalization was highest (94%) among patients
with 2 or more comorbid conditions. In 2014 and 2015, as many
as 95% of the patients hospitalized for opioid-related causes had 2
or more comorbid conditions.
The prevalence of opioid-related hospitalizations significantly in-
creased among patients with cancer, stroke, obesity, asthma, liver
disease, and arthritis across all years (Table 2). The most preval-
ent chronic disease significantly associated with opioid-related
hospitalization was asthma, followed by obesity and liver disease.
There was a significant association between opioid-related hospit-
alization and cancer, stroke, obesity, asthma, and liver disease
every year of the study period, with the exception of cancer in
2013 and obesity in 2015. The association between arthritis and
opioid-related hospitalizations was significant only in 2014 and
2015, and the association between spinal diseases and opioid-re-
lated hospitalizations was significant only in 2012 and 2015.
Discussion
We found that more than 90% of opioid-related hospitalizations
were among patients with 2 or more chronic diseases and that the
trend in opioid-related hospitalization among patients with chron-
ic diseases is increasing. This finding is salient given that 1 in 4
US adults are living with 2 or more chronic diseases (13). Both the
opioid crisis  and rising rates of chronic disease have been de-
scribed as epidemics; however, they are currently being treated
separately. The US Department of Health and Human Services’ 5-
point strategy to combat the opioid crisis focuses on the treatment
of addiction, which is important for addressing the epidemic in the
short term (14). A population-level approach to preventing and
treating chronic diseases is also needed. Health services must ad-
dress the 2 issues — opioid misuse and management of chronic
disease — simultaneously.
Using alternative approaches to pain management is one public
health strategy for addressing the opioid crisis (15) and is consist-
ent with the Centers for Disease Control and Prevention’s (CDC’s)
Guideline for Prescribing Opioids for Chronic Pain (16). Based on
our findings, this approach may be particularly important in pa-
tients with multiple chronic diseases. Consistent with the CDC
guideline, nonpharmacologic treatment including exercise therapy
and cognitive behavioral therapy, as well as multimodal therapies
combining  exercise  therapy  with  psychologically  based  ap-
proaches, should be used to decrease pain and improve functional
ability (16). When opioids are used for pain management, patients
with multiple chronic diseases may require close monitoring and
additional education on risks of misuse.
This study has several limitations. Because we analyzed data from
2011 to 2015, our findings are not generalizable to more recent
years. Our analysis was cross-sectional and examined the associ-
ations between opioid-related hospitalization and chronic diseases
without controlling for covariates, which prevents us from draw-
ing causal conclusions about the direction of the observed relation-
ship. Furthermore, the nature of the data did not allow us to ex-
plore why the associations were not significant in some years.
Opioid prescriptions for patients with arthritis have increased in
recent years, so that could be an explanation for the strong correla-
tion we found (17). Finally, we studied a small number of chronic
diseases and did not assess any diseases related to mental health.
Despite these limitations, our findings show an increasing trend in
opioid-related hospitalization among patients with chronic dis-
eases  and  a  high  prevalence  of  opioid-related  hospitalization
among patients with multiple chronic conditions. The observed as-
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sociation warrants further research to determine causal inference.
Results from this study can help clinicians develop strategies to
prevent opioid misuse in patients with multiple chronic conditions
and inform strategies for addressing both the opioid epidemic and
rising rates of chronic disease.
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Tables
Table 1. Prevalence of Opioid-Related Hospitalizations Among Adults Aged 18 or Older, National Inpatient Sample, 2011–2015a
Characteristic
Yearb
2011 (n = 639,586) 2012 (n = 655,520) 2013 (n = 664,480) 2014 (n = 704,670) 2015 (n = 574,880)
Age, y
18–34 29.35 30.30 30.37 29.98 29.22
35–54 39.51 38.23 37.07 36.29 35.97
55–64 15.86 16.50 17.06 17.60 18.37
≥65 15.29 14.97 15.50 16.12 16.44
Sex
Male 49.73 49.34 49.02 49.15 49.63
Female 50.27 50.66 50.98 50.85 50.37
Race/ethnicity
White 70.76 71.26 72.67 73.16 72.99
Black 16.30 15.36 14.22 14.12 14.44
Hispanic 8.33 8.70 8.79 8.30 8.38
Asian 0.69 0.78 0.75 0.84 0.88
Native American 0.65 0.70 0.65 0.74 0.77
Other 3.27 3.20 2.84 2.84 2.59
No. of comorbidities
None 0.69 0.57 0.54 0.39 0.40
One 5.39 5.41 4.97 4.49 4.23
Two or more 93.91 94.02 94.48 95.12 95.37
Rural/urban status
Rural 35.59 40.81 42.04 41.57 41.71
Urban 64.41 59.19 57.96 58.43 58.29
Payer
Medicaid 30.74 31.61 31.29 37.66 39.30
Medicare 30.20 30.62 31.56 31.85 31.53
Private 21.22 21.06 20.72 19.62 19.61
Self-pay 13.35 12.19 12.02 7.80 6.45
Other 4.49 4.52 4.41 3.08 3.11
a Data are percentages, per 100,000 hospitalizations; sampling weight adjusted in all statistics.
b Values for n indicate the total number of opioid-related hospitalizations for the year.
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Table 2. Prevalence of Opioid-Related Hospitalizations Among Adults Aged 18 or Older, by Chronic Disease, National Inpatient Sample, 2011–2015a
Chronic Disease
Year
P Valueb2011 2012 2013 2014 2015
Cancer 1.11c 1.16c 1.32 1.40c 1.58c <.001
Stroke 0.90c 0.93c 1.04c 1.04c 1.07c <.001
Obesity 8.18c 8.92c 9.67c 10.21c 10.80 <.001
Asthma 10.77c 11.18c 10.93c 11.49c 11.91c <.001
Liver Disease 4.76c 4.77c 5.12c 5.21c 5.35c <.001
Spinal Disease 0.83 0.75d 0.77 0.77 0.80c .09
Arthritis 1.65 1.67 1.73 1.83d 1.96c <.001
a Data are percentages, per 100,000 hospitalizations; sampling weight adjusted in all statistics.
b Trend analysis was calculated by using χ2 test.
c P < .001. P values calculated by using  test.
d P < .05. P values calculated by using  test.
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Appendix A. International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) Diagnosis Codes Used to Identify Opioid-Related
Hospitalization
Hospitalization Type ICD-9-CM Code
Opioid dependence and unspecified use 304.00, 304.01, 304.07, 304.71
Adverse effects of opioids E935.1, E935.2, E940.1
Opioid abuse 305.50, 305.51, 305.52
Opioid poisoning 965.00, 965.01, 965.02, 965.09, 970.1, E850.0, E850.1, E850.2
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Appendix B. International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) Diagnosis Codes Used to Identify Comorbidities
Comorbidity ICD-9-CM Code
Cancer
Buccal cavity and pharynx 140.00 to 149.00
Digestive system 150.00 to 159.00
Respirator system 160.00 to 165.00
Bones and joints 170.00
Soft tissue including heart 171.00
Skin 172.00 to 173.00
Breast 174.00 to 175.00
Kaposi’s sarcoma 176.00
Female genital system 179.00, 180.00 to 184.00
Male genital system 185.00 to 187.00
Urinary system 188.00 to 189.00
Eye and orbit 190.00
Brain and other nervous system 191.00 to 192.00
Endocrine system 164.00, 193.00 to 194.00
Ill-defined 195.00 to 196.00, 199.00, 202.00
Lymphoma 200.00 to 202.00, 202.10, 202.20, 202.80, 202.90
Multiple myeloma 203.00, 203.80
Leukemia 202.40, 203.10, 204.00 to 208.00
Benign neoplasms 210.00 to 229.00
Carcinoma in situ 230.00 to 234.00
Neoplasms of uncertain behavior 235.00 to 238.00
Neoplasms of unspecified nature 239.00
Stroke
Occlusion and stenosis of basilar artery 433.01, 433.10, 433.11, 433.21, 433.31, 433.81, 433.91
Cerebral thrombosis with/without cerebral infarction 434.00, 434.01, 434.11, 434.91
Acute, but ill-defined, cerebrovascular 436.00
Subarachnoid hemorrhage 430.00
Intracerebral hemorrhage 431.00
Asthma
Extrinsic asthma 493.00, 493.01, 493.02
Intrinsic asthma 493.10, 493.11, 493.12
Chronic obstructive asthma 493.20, 493.21, 493.22
Other forms of asthma 493.81, 493.82
Asthma unspecified 493.90, 493.91, 493.92
Liver disease
Acute and subacute necrosis of liver 570.0
Chronic liver disease and cirrhosis 571.0, 571.1, 571.2, 571.3, 571.4, 571.5, 571.6, 571.8, 571.9
(continued on next page)
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(continued)
Comorbidity ICD-9-CM Code
Liver abscess 572.0. 572.1, 572.2, 572.3, 572.4, 572.8
Other disorders of liver 573.0, 573.1, 573.2, 573.3, 573.4, 573.5, 573.6, 573.8, 573.9
Arthritis
Psoriatic arthritis 696.0
Diffuse disease of connective tissue 710.0. 710.1. 710.2. 710.3, 710.4, 710.5, 710.8, 710.9
Infectious arthropathies 711.0, 711.1, 711.2, 711.3, 711.4, 711.5, 711.6, 711.7, 711.8, 711.9
Crystal arthropathies 712.1, 712.2, 712.3, 712.8, 712.9
Rheumatoid arthritis 714.0. 714.2, 714.3, 714.4, 714.8, 714.9
Osteoarthritis and allied disorders 715.0, 715.1, 715.2 715.3, 715.8, 715.9
Other/unspecified arthropathies 716.0, 716.1, 716.2, 716.3, 716.5, 716.6, 716.8, 716.9
Obesity
Obesity 278.00
Morbid obesity 278.01
Overweight 278.02
Obesity hypoventilation syndrome 278.03
Spinal disease
Spondylosis 721.0
Intervertebral disc disorder 722.0
Other cervical disorders 723.0
Low back pain 724.0
PREVENTING CHRONIC DISEASE VOLUME 16, E157
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY   NOVEMBER 2019
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
8       Centers for Disease Control and Prevention  •  www.cdc.gov/pcd/issues/2019/19_0169.htm
